PLETAL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pletal, and when can generic versions of Pletal launch?
Pletal is a drug marketed by Otsuka and is included in one NDA.
The generic ingredient in PLETAL is cilostazol. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cilostazol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pletal
A generic version of PLETAL was approved as cilostazol by EPIC PHARMA LLC on November 23rd, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PLETAL?
- What are the global sales for PLETAL?
- What is Average Wholesale Price for PLETAL?
Summary for PLETAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 128 |
| Clinical Trials: | 20 |
| Patent Applications: | 4,208 |
| DailyMed Link: | PLETAL at DailyMed |
Recent Clinical Trials for PLETAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Asan Medical Center | Phase 4 |
| Kangbuk Samsung Hospital | Phase 4 |
| University of Edinburgh | Phase 2 |
US Patents and Regulatory Information for PLETAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | PLETAL | cilostazol | TABLET;ORAL | 020863-001 | Jan 15, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Otsuka | PLETAL | cilostazol | TABLET;ORAL | 020863-002 | Jan 15, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PLETAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Otsuka | PLETAL | cilostazol | TABLET;ORAL | 020863-001 | Jan 15, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Otsuka | PLETAL | cilostazol | TABLET;ORAL | 020863-002 | Jan 15, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PLETAL
See the table below for patents covering PLETAL around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
